[{"indications": "Indications\u00a0see restrictions above", "name": "CO-TRIMOXAZOLE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.8 Sulfonamides and trimethoprim"], "cautions": "Cautions\u00a0 maintain adequate fluid intake; avoid\r\nin blood disorders (unless under specialist supervision); monitor blood counts on prolonged treatment; discontinue immediately if blood disorders or rash\r\ndevelop; predisposition to folate deficiency or hyperkalaemia; elderly (see Restrictions on the\r\nuse of Co-trimoxazole above); asthma; G6PD deficiency (section 9.1.5); avoid in infants under 6 weeks\r\n(except for treatment or prophylaxis of pneumocystis pneumonia); interactions: Appendix 1 (trimethoprim, sulfamethoxazole)", "side-effects": "Side-effects\u00a0nausea, diarrhoea; headache; hyperkalaemia; rash\r\n(very rarely including Stevens-Johnson syndrome, toxic epidermal necrolysis,\r\nphotosensitivity)\u2014discontinue immediately; less commonly vomiting; very rarely glossitis, stomatitis, anorexia,\r\nliver damage (including jaundice and hepatic necrosis), pancreatitis,\r\nantibiotic-associated colitis, myocarditis, cough and shortness of\r\nbreath, pulmonary infiltrates, aseptic meningitis, depression, convulsions,\r\nperipheral neuropathy, ataxia, tinnitus, vertigo, hallucinations,\r\nhypoglycaemia, blood disorders (including leucopenia, thrombocytopenia,\r\nmegaloblastic anaemia, eosinophilia), hyponatraemia, renal disorders\r\nincluding interstitial nephritis, arthralgia, myalgia, vasculitis,\r\nsystemic lupus erythematosus and uveitis; rhabdomyolysis reported\r\nin HIV-infected patients", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3884.htm", "doses": ["By mouth, 960\u00a0mg every 12 hours; child, every 12 hours, 6 weeks\u20135 months, 120\u00a0mg;\r\n6 months\u20135 years, 240\u00a0mg; 6\u201312 years, 480\u00a0mg", "By intravenous infusion, 960\u00a0mg every 12 hours\r\nincreased to 1.44\u00a0g every 12 hours in severe infections; child 36\u00a0mg/kg daily in 2 divided doses increased\r\nto 54\u00a0mg/kg daily in severe infections", "Treatment of Pneumocystis jirovecii (Pneumocystis carinii) infections (undertaken where facilities\r\nfor appropriate monitoring available\u2014consult microbiologist and product\r\nliterature), by mouth or by\r\nintravenous infusion, adult and child over 4 weeks, 120\u00a0mg/kg\r\ndaily in 2\u20134 divided doses for 14\u201321 days", "Prophylaxis of Pneumocystis jirovecii (Pneumocystis carinii) infections, by mouth, 960\u00a0mg once daily (may be reduced to 480\u00a0mg once daily to improve\r\ntolerance) or 960\u00a0mg on alternate days (3 times a\r\nweek) or 960\u00a0mg twice daily on alternate days (3\r\ntimes a week); child 6 weeks\u20135 months,\r\n120\u00a0mg twice daily on 3 consecutive or alternate days per week or on 7 days per week; 6 months\u20135 years, 240\u00a0mg; 6\u201312 years,\r\n480\u00a0mg", "480\u00a0mg of co-trimoxazole consists of sulfamethoxazole 400\u00a0mg and trimethoprim 80\u00a0mg"], "pregnancy": "Pregnancy\u00a0teratogenic risk in first trimester (trimethoprim\r\na folate antagonist). Neonatal haemolysis and methaemoglobinaemia\r\nin third trimester; fear of increased risk of kernicterus in neonates\r\nappears to be unfounded"}]